Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

872 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Farnesyl transferase expression determines clinical response to the docetaxel-lonafarnib combination in patients with advanced malignancies.
Kauh J, Chanel-Vos C, Escuin D, Fanucchi MP, Harvey RD, Saba N, Shin DM, Gal A, Pan L, Kutner M, Ramalingam SS, Bender L, Marcus A, Giannakakou P, Khuri FR. Kauh J, et al. Among authors: gal a. Cancer. 2011 Sep 1;117(17):4049-59. doi: 10.1002/cncr.26004. Epub 2011 Mar 1. Cancer. 2011. PMID: 21365629 Free PMC article. Clinical Trial.
Phase II study of docetaxel in combination with everolimus for second- or third-line therapy of advanced non-small-cell lung cancer.
Ramalingam SS, Owonikoko TK, Behera M, Subramanian J, Saba NF, Kono SA, Gal AA, Sica G, Harvey RD, Chen Z, Klass CM, Shin DM, Fu H, Sun SY, Govindan R, Khuri FR. Ramalingam SS, et al. Among authors: gal aa. J Thorac Oncol. 2013 Mar;8(3):369-72. doi: 10.1097/JTO.0b013e318282709c. J Thorac Oncol. 2013. PMID: 23407561 Free PMC article. Clinical Trial.
A Translational, Pharmacodynamic, and Pharmacokinetic Phase IB Clinical Study of Everolimus in Resectable Non-Small Cell Lung Cancer.
Owonikoko TK, Ramalingam SS, Miller DL, Force SD, Sica GL, Mendel J, Chen Z, Rogatko A, Tighiouart M, Harvey RD, Kim S, Saba NF, Pickens A, Behera M, Fu RW, Rossi MR, Auffermann WF, Torres WE, Bechara R, Deng X, Sun SY, Fu H, Gal AA, Khuri FR. Owonikoko TK, et al. Among authors: gal aa. Clin Cancer Res. 2015 Apr 15;21(8):1859-68. doi: 10.1158/1078-0432.CCR-14-1998. Epub 2015 Feb 11. Clin Cancer Res. 2015. PMID: 25673697 Free PMC article. Clinical Trial.
Management of a patient with stage IIIA (N2) NSCLC.
Carlson K, Fowler BZ, Miller DL, Gal A, Ramalingam S. Carlson K, et al. Among authors: gal a. Oncology (Williston Park). 2008 Apr 30;22(5):553-7; discussion 557-9. Oncology (Williston Park). 2008. PMID: 18533405 Review.
Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.
Fisher KE, Zhang L, Wang J, Smith GH, Newman S, Schneider TM, Pillai RN, Kudchadkar RR, Owonikoko TK, Ramalingam SS, Lawson DH, Delman KA, El-Rayes BF, Wilson MM, Sullivan HC, Morrison AS, Balci S, Adsay NV, Gal AA, Sica GL, Saxe DF, Mann KP, Hill CE, Khuri FR, Rossi MR. Fisher KE, et al. Among authors: gal aa. J Mol Diagn. 2016 Mar;18(2):299-315. doi: 10.1016/j.jmoldx.2015.11.006. Epub 2016 Jan 20. J Mol Diagn. 2016. PMID: 26801070 Free PMC article.
Prognostic factors in pulmonary fibrohistiocytic lesions.
Gal AA, Koss MN, McCarthy WF, Hochholzer L. Gal AA, et al. Cancer. 1994 Apr 1;73(7):1817-24. doi: 10.1002/1097-0142(19940401)73:7<1817::aid-cncr2820730708>3.0.co;2-k. Cancer. 1994. PMID: 8137205
LKB1 mutation in large cell carcinoma of the lung.
Zhong D, Guo L, de Aguirre I, Liu X, Lamb N, Sun SY, Gal AA, Vertino PM, Zhou W. Zhong D, et al. Among authors: gal aa. Lung Cancer. 2006 Sep;53(3):285-94. doi: 10.1016/j.lungcan.2006.05.018. Epub 2006 Jul 5. Lung Cancer. 2006. PMID: 16822578
872 results